Back to top
more

Retrophin, Inc. (RTRX)

(Delayed Data from NSDQ)

$19.72 USD

19.72
376,763

+0.61 (3.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $19.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Retrophin (RTRX) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retrophin (RTRX) Catches Eye: Stock Jumps 6.9%

by Zacks Equity Research

Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    Are Options Traders Betting on a Big Move in Retrophin (RTRX) Stock?

    by Zacks Equity Research

    Investors in Retrophin (RTRX) need to pay close attention to the stock based on moves in the options market lately.

      Options Traders Expect Huge Moves in Retrophin (RTRX) Stock

      by Zacks Equity Research

      Investors in Retrophin (RTRX) need to pay close attention to the stock based on moves in the options market lately.

        Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo

        by Zacks Equity Research

        Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.

          Pacira Focuses on Lead Candidate Exparel's Label Expansion

          by Zacks Equity Research

          We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.

            Ohr Pharmaceutical Provides Update on Squalamine Study

            by Zacks Equity Research

            Ohr Pharmaceutical, Inc. (OHRP), announced it plans to amend the ongoing MAKO Study evaluating Squalamine (also known as OHR-102) in wet form of age-related macular degeneration (wet-AMD).

              Endo (ENDP) Reports Preliminary Results for First Quarter

              by Zacks Equity Research

              Endo International plc (ENDP) recently announced preliminary results for first-quarter 2017.

                Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion

                by Zacks Equity Research

                Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.

                  Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA

                  by Zacks Equity Research

                  Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.

                    Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst

                    by Zacks Equity Research

                    Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.

                      Valeant (VRX) Faces Pricing Issues, Generic Threats Loom

                      by Zacks Equity Research

                      Shares of Valeant Pharmaceuticals International, Inc. (VRX) hit a 52-week low of $10.08 on Apr 4.

                        Galapagos Initiates 3 Phase II Studies for Filgotinib

                        by Zacks Equity Research

                        Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.

                          Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo

                          by Zacks Equity Research

                          Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.

                            Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA

                            by Zacks Equity Research

                            Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.

                              Bayer Announced Positive Data for Cancer Drug Copanlisib

                              by Zacks Equity Research

                              Bayer Aktiengesellschaft (BAYRY) announced positive data on its experimental candidate copanlisib.

                                GlaxoSmithKline Initiates Phase III Study with Mepolizumab

                                by Zacks Equity Research

                                GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES).

                                  BioDelivery to Grant New Patents for its Marketed Drugs

                                  by Zacks Equity Research

                                  BioDelivery Sciences (BDSI) recently announced its decision to grant two new patents to extend the patent life for all three of its marketed products, Belbuca , Bunavail, and Onsolis.

                                    Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate

                                    by Zacks Equity Research

                                    Spectrum Pharmaceuticals (SPPI) recently announced that it has initiated a phase II trial to evaluate its pipeline candidate, poziotinib for the treatment of non-small cell lung cancer patients.

                                      Roche's Rituxan Gets FDA Advisory Committee's Recommendation

                                      by Zacks Equity Research

                                      Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.

                                        Bill Ackman Apologizes for Valeant Investment Error

                                        by Zacks Equity Research

                                        In a letter addressed to shareholders, Bill Ackman, chairman of Perishing Square Holdings, Ltd stated that investing in Valeant Pharmaceuticals (VRX) was a big mistake on his part.

                                          Acorda Presents Data for Parkinson's Candidate CVT-301

                                          by Zacks Equity Research

                                          Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.

                                            Amgen's Leukemia Drug Accepted for Priority Review by FDA

                                            by Zacks Equity Research

                                            Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.

                                              Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis

                                              by Zacks Equity Research

                                              Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.

                                                Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage

                                                by Zacks Equity Research

                                                Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.